Disclaimer
For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
Who is Left Atrial Appendage Closure Therapy For?
Consider LAA Closure Therapy for your patients with non-valvular AF, at high risk of stroke and:
- Contraindication to oral anticoagulation1
- Intolerance to oral anticoagulation2
- Elevated bleeding risk (HAS-BLED>=3; Elevated bleeding risk outside HAS-BLED-Score; Need for prolonged or repetitive triple therapy; Renal failure (severe) as contraindication to NOAC)1
- Individual and specific anticoagulation risk constellation for stroke (Inefficient OAC; Electrically isolated LAA post ablation (indication for LAA occlusion controversial)1
Why WATCHMAN FLX?
WATCHMAN FLX leverages the experience of the proven and safe WATCHMAN platform. WATCHMAN FLX effectively reduces the risk of stroke and the long term risk of bleeding associated with OAC use in patients with non-valvular AF.
LAAC Guidelines & Recommendations:
- 2020 ESC Guidelines for the management of atrial fibrillation2
- EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion1
REFERENCES
1. Glikson M, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2019 Aug 31. pii: euz258. doi: 10.1093/europace/euz258
2. Kirchhof P et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962For OAC contraindications, refer to Instructions for use of anticoagulant drugs.
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.